No profile data available.
Enzolytics, Inc. (ENZC) is a healthcare company in the immunodeficiency treatment drugs industry, based in Plano, United States.
It reported revenue of $36,968 for fiscal year 2010, up 151.3% from fiscal year 2009, and net income of -$7.51 million. In Q2 2011 (the quarter ended June 30, 2011) revenue was $15,350, up 89.0% from a year before. Its market capitalization was $1.93 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2010; market data as of October 9, 2026.
Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy.
Enzolytics reported $36,968 in revenue for fiscal year 2010, up 151.3% from $14,708 in fiscal year 2009. In Q2 2011 revenue was $15,350.
$1.93 million as of October 9, 2026.
Listed companies of a similar size in the same industry (immunodeficiency treatment drugs) include Pharming Group N.v. (PHAR), X4 Pharmaceuticals, Inc. (XFOR), AIM ImmunoTech Inc. (AIM), Biostax Corp. (BTAX).